Direct‐acting antivirals (DAA) for hepatitis C virus (HCV) became available in 2014, but the
role of mental health or substance use disorders (MH/SUD) on access to treatment is …

Human immunodeficiency virus (HIV) and hepatitis C virus (HCV) coinfection carries
substantial risk for all-cause mortality and liver-related morbidity and mortality, yet many …

Medicaid prior authorization (PA) policies for treatment of hepatitis C virus (HCV) with direct‐
acting antiviral (DAA) therapy are changing. We aimed to evaluate effects of changes in PA …

There are limited data examining the relationship between psychosocial factors and receipt
of direct‐acting antiviral (DAA) treatment among patients with hepatitis C in large health care …

Outcomes related to alcohol use after hepatitis C virus (HCV) treatment are unknown in the
direct‐acting antiviral (DAA) era. We assessed levels of alcohol use before and after HCV …

BACKGROUND Many veterans may not be candidates for hepatitis C virus (HCV) treatment
due to contraindications to therapy. The aims of this study were to determine the proportion …

Objective Direct acting antivirals (DAAs) have overcome many long-standing medical
barriers to hepatitis C virus (HCV) treatment (ie host characteristics and medical …

Background and Aims Our aim was to evaluate the impact of direct‐acting antivirals (DAAs)
on decompensated cirrhosis (DCC) and HCC in patients with chronic HCV and substance …

Objectives: The cost of direct-acting antiviral agents (DAAs) for hepatitis C virus (HCV)
infection may contribute to treatment disparities. However, few data exist on factors …

Background Direct‐acting anti‐virals (DAA) are safe, effective treatment of hepatitis C virus
(HCV). Suboptimal linkage to specialists and access to DAA s are the leading barriers to …